Mumbai: Marksans Pharma Limited has announced that its wholly owned subsidiary Relonchem
Limited has received Marketing Authorization for the product Sennosides 7.5 mg Tablets
from UK Medicines & Healthcare Products Regulatory Agency.Last week, Relonchem also received marketing authorization for Gabapentin 50 mg/ml oral solution from UK Medicines & Healthcare Products Regulatory Agency.Read also: After Baclofen, now Gabapentin: Marksans Pharma arm bags another UK MHRA green lightMarksans Pharma Limited headquartered at Mumbai, India is
engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in
the global markets. The company’s manufacturing facilities located in India, USA and UK are
approved by several leading regulatory agencies including USFDA, UKMHRA and
Australian TGA. The company’s product portfolio spreads over major therapeutic
segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological and Antiallergies. The company is marketing these products globally.Read also: After Baclofen, now Gabapentin: Marksans Pharma arm bags another UK MHRA green light